Aperiam Bio, founded with a mission to revolutionize protein optimization, partners with enzyme engineers to create stabilized, solubilized, and catalytically optimized proteins. The company focuses on identifying hyperfolding variants of target proteins, achieving tenfold improvements in expression, solubility, and specific activity. Aperiam Bio aims to deliver significant advancements in protein engineering, targeting markets that require high-performance enzymes and proteins.
Notable achievements include the awarding of patent claims by the USPTO for their innovative use of computer vision in identifying stabilizing mutations. Emerging from stealth mode with substantial funding, Aperiam Bio has made a significant impact by streamlining and enhancing protein solutions. Their work promises to advance various industries reliant on optimized proteins, from pharmaceuticals to industrial biotechnology.
